Head and neck squamous cell carcinomas (HNSCC) manifest various clinical behaviors according to their origin, i.e., from various parts of the head and neck mucosa. However, genetic factors involved in the carcinogenesis of HNSCC in different tissues have not yet been studied and evaluated. Three hundred and two specimens of HNSCC were characterized for allelic loss of certain areas of the genome, i.e., 3p21, 9p21 and 17p13, and were examined for genetic factors that might correlate with the tissue specificity of HNSCC and influence their clinical features. Loss of heterozygosity (LOH) at 3p21, 9p21 and 17p13 was detected in 54.5%, 57.4% and 57.1% of the informative cases, respectively. The frequencies of LOH in hypopharyngeal and in laryngeal cancers were significantly higher than in oral cancers. There were significant correlations between LOH at 3p21 and lymph node involvement and between LOH at 17p13 and tumor size, resulting in positive correlations with clinical stage of HNSCC in the patients. These results indicate that not only the functions of tumor suppressor genes differ among HNSCC in various regions, but also that allelic loss plays a key role in the acquisition of a malignant phenotype of these tumors.
and arf, are located at 9p21 while the p53 gene is located at 17q13. In addition, 3p21 is thought to have tumor suppressor gene(s) that have not yet been characterized and this locus has been reported to have LOH in various cancers originating from the upper aerodigestive tract (Horio et al. 1993; Maestro et al. 1993; Mitsudomi et al. 1996; Partridge et al. 1996) .
We reported previously that LOH at 9p21 occurs in HNSCC that have a more malignant phenotype and which frequently recur (Matsuura et al. 1998 ). However, there was no significant correlation between these LOH and clinical features of the patients, i.e., tumor size (T), lymph node involvement (N), clinical staging, and so on. To examine whether those results simply reflect the small number of samples, we have increased the number of samples from HNSCC patients and have re-examined them for LOH.
In this study, we thus examined the frequency of LOH at the 3p21, 9p21 and 17p13 loci and analyzed their possible correlation with clinical factors in HNSCC patients.
MATERIALS AND METHODS

Patients and tissue specimens
Primary tumors were removed surgically or were obtained as biopsies before treatment during the period from May 1994 to November 2000, following approved protocols at the Miyagi Cancer Center. After surgical removal or biopsy, specimens were frozen immediately and stored at −110°C. A total of 302 samples were studied and all were diagnosed as squamous cell carcinoma by pathological examination. These were comprised of 17 carcinomas of the nasal or paranasal cavity, 2 of the lip and 99 oral cancers (71 cancers of the tongue, 13 cancers of the floor of mouth, 8 cancers of the gingiva and 7 cancers of the buccal mucosa), 7 epipharyngeal cancers, 34 mesopharyngeal cancers, 60 hypopharyngeal cancers, 85 laryngeal cancers, 1 skin cancer, 4 cancers of the external auditory canal and 1 primary unknown neck cancer. The clinical features of the patients are summarized in Table 1. The stage grouping The idea of the multi-step process of carcinogenesis is now generally accepted. Human cancers result from a multi-step pathogenesis associated with the progressive accumulation of mutations in key cellular genes, some of which are tumor suppressor genes while others are oncogenes (Knudson 1985; James et al. 1988; Vogelstein et al. 1988; Fearon and Vogelstein 1990; Dalbagni et al. 1993) . In fact, loss of the functions of tumor suppressor genes, caused by deletions, point mutations or methylation, has been shown to play a crucial role in the transformation of malignant cells. In head and neck squamous cell carcinoma (HNSCC), genetic alterations of specific loci, i.e., 9p, 17p, 3p and 13q, are thought to be involved in the malignant transformation of epithelial cells in the mucosa of the head and neck regions (Maestro et al. 1993; Adamson et al. 1994; Nawroz et al. 1994; van der Riet et al. 1994; Huang et al. 1994; Yokoyama et al. 1996) . In addition, although mutations of both alleles of a tumor suppressor gene are needed to trigger tumor formation according to Knudson's classic two-hit theory of tumorigenesis (Knudson 1985) , a new theory proposes that mutation or loss of a single allele may be sufficient to exert a cellular phenotype that leads to tumorigenesis without inactivation of the second allele (Fero et al. 1998; Venkatachalam et al. 1998; Song et al. 1999; Goss et al. 2002; Spring et al. 2002) . This gene-dosage effect, i.e., haploinsufficiency, may play a crucial role in the carcinogenesis of HNSCC and characterization of allelic loss in these tumors may have an important meaning from this point of view.
In hospital clinics, physicians wonder what factors distinguish the tissue specificity of HNSCC because the clinical features vary greatly among patients bearing tumors in different regions of the head and neck. To determine which genetic factor(s) contribute to the clinical features of patients with HNSCC, we focused on the allelic loss of chromosomes, i.e., loss of heterozygosity (LOH) of 3p21, 9p21 and 17p13. It is well known that the tumor suppressor genes, p15, p16 #Patients who had recurrent lymph node metastasis are omitted in this classification. NS, not significant. and the TNM system of the patients were defined according to the Union International Contre le Cancer (UICC, 1987) . All patients, except for patients with stage I or II laryngeal cancer or epipharyngeal cancer, were treated by wide tumor resection and all patients with metastases in neck lymph node(s) were treated by neck dissection. Patients with stage I or II laryngeal cancer were treated by radiation therapy, while those with epipharyngeal cancer were treated by chemo-radiation therapy.
DNA preparation
Genomic DNA was extracted from the frozen tissue samples using Proteinase K (Boehringer Mannheim, Mannheim, Germany) digestion and phenol extraction according to standard methods (Shiga et al. 1990 (Shiga et al. , 1992 . Peripheral blood lymphocytes were used as the normal counterparts for these experiments.
PCR amplification
Polymorphic markers, D3S1067, IFNA D9S171 and TP53, were purchased from Invitrogen (Carlsbad, CA, USA) and each forward primer of those markers was labeled using [γ -32 p] ATP and polynucleotide kinase (Takara Shuzo, Kyoto). The PCR reaction mixture consisted of 0.2-1.0 μ g extrtacted DNA, 1 pmol of forward primer, 5 pmol of reverse primer, 0.2 mM of all four deoxynucleotide triphosphates (dNTP), reaction buffer and 5 units of Taq DNA polymerase (Boehringer Mannheim) in a total volume of 50 μ l. PCR was performed using a Thermal Cycler (Perkin Elmer Cetus, Boston, MA, USA) (Yokoyama et al. 1996; Matsuura et al. 1998; Shiga et al. 2003) for 36 cycles under optimal conditions, i.e., 1 minute at 94°C, 1 minute at 56°C and 1 minute at 72°C, except for the first denaturing process which was done at 94°C for 5 minutes. Purified PCR products were separated by electrophoresis on 6% polyacrylamide gels containing 8.3 M urea.
Statistical analysis
Statistical analyses of the data were performed by the χ 2 test and t-test.
RESULTS
A total of 302 specimens of HNSCC were studied to examine whether or not there was allelic loss at 3p21, 9p21 and/or 17p13. Typical results are shown in Fig. 1 . As shown in Tables 1  and 2A , when D3S1067 was used as the polymorphic microsatellite probe, 217 out of 302 (71.8%) samples that could be evaluated were heterozygotes, i.e., informative and LOH was detected in 96 cases (44.0%). Three out of 11 cases (27%) of maxillary cancers had LOH at the 3p21 locus, as did 12 out of 52 (23%) cases of tongue cancers, 21 out of 70 cases (30%) of oral cancers including tongue cancers, 12 out of 24 cases (50%) of mesopharyngeal cancers, 25 out of 40 cases (63%) of hypopharyngeal cancers, 38 out of 69 cases (55%) of pharyngeal cancers including hypopharyngeal cancers and 29 out of 60 cases (48%) of laryngeal cancers. Table 2A shows the relationship between the localization of each tumor and the frequency of LOH at the 3p21 locus. The frequency of LOH at 3p21 in hypopharyngeal cancers was significantly higher than that of maxillary cancers, oral cancers and tongue cancers (p=0.038, p=0.0009 and p=0.0001, respectively). At the same time, the frequency of LOH at 3p21 in pharyngeal cancers including hypopharyngeal cancers was significantly higher than that of oral cancers and tongue cancers (p=0.0028 and p=0.0004, respectively). On the other hand, the frequency of LOH at 3p21 in laryngeal cancers was significantly higher than that of oral cancers and tongue cancers (p=0.032 and p=0.0057, respectively).
We used two markers to analyze LOH at 9p21 because of the low informativity of IFNA and D9S171. When IFNA and D9S171 were used as polymorphic probes to detect LOH at 9p21, 206 out of 302 (68.2%) samples that could be evaluated were heterozygote, i.e., informative and LOH was detected in 93 cases (45.1%). The consistency of LOH between IFNA and D9S171 was Table 2C shows the relationship between the localization of each tumor and the frequency of LOH at the 17p13 locus. The frequency of LOH at 17p13 in hypopharyngeal cancers was significantly higher than that of oral cancers and tongue cancers (p=0.027 and p=0.0094, respectively). At the same time, the frequency of LOH at 17p13 in pharyngeal cancers including hypopharyngeal cancers was significantly higher than that of oral cancers and tongue cancers (p=0.0048 and p=0.019, respectively). On the other hand, the frequency of LOH at 17p13 in laryngeal cancers was significantly higher than that of oral cancers (p=0.026). These results are summarized and shown as a bar graph in Fig. 2 . We analyzed the relationship between the clinical features of patients and the frequency of LOH at the 3p21, 9p21 and 17p13 loci ( Table 1) . As for age, the frequency of LOH at the 3p21 and 9p21 loci was apparently higher in older patients and there was a significant difference at the 9p21 locus. As for gender, the frequency of LOH appeared to be higher in males at all three loci, but there was no significant difference between the frequencies of LOH in males and in females.
The frequency of LOH at the 3p21 locus in T1, T2, T3 and T4 tumors was 18 out of 35 (51%), 28 out of 79 (35%), 23 out of 54 (43%) and 20 out of 40 (50%), respectively. The frequency of LOH appeared to be slightly higher in T3 and T4 tumors but the difference was not statistically significant. The frequency of LOH at the 3p21 locus in N0, N1, N2, and N3 tumors was 45 out of 121 (37.2%), 9 out of 23 (39%), 37 out of 64 (58%) and 3 out of 6 (50%), respectively. The frequency of LOH was significantly higher in lymph node metastasis positive tumors than that of lymph node negative tumors (p=0.015). The frequency of LOH at the 3p21 locus in stages I, II, III and IV cases was 16 out of 31 (52%), 12 out of 48 (25%), 17 out of 41 (41%) and 49 out of 94 (52%), respectively. The frequency of LOH was not only significantly higher in the stage IV cases than in the stage II cases (p=0.002) but was also significantly higher in the advanced stage cases (stages III and IV) than in the early stage cases (stages I and II) (p=0.047).
The frequency of LOH at the 9p21 locus in T1, T2, T3 and T4 tumors was 20 out of 38 (53%), 29 out of 76 (38%), 22 out of 53 (42%) and 20 out of 32 (63%), respectively. The frequency of LOH was significantly higher in the T4 tumors than in the T2 tumors (p=0.025). The frequency of LOH at the 9p21 locus in stages I, II, III and IV cases was 15 out of 32 (47%), 27 out of 55 (49%), 15 out of 39 (38%) and 45 out of 86 (52%), respectively. The frequency of LOH appeared to be slightly higher in advanced cases (stage IV) than in early stage cases (stages I and II) but the difference was not statistically significant. The frequency of LOH at the 17p13 locus in T1, T2, T3 and T4 tumors was 12 out of 31 (39%), 36 out of 66 (55%), 23 out of 34 (68%) and 24 out of 31 (77%), respectively. The frequency of LOH appeared to become higher and higher as the T number of the tumors became higher. The frequency of LOH was not only significantly higher in the T4 tumors than in the T1 tumors (p=0.002) but was also significantly higher in the T3 tumors than in the T1 tumors (p=0.019). At the same time, the frequency of LOH was also significantly higher in the advanced tumors (T3 and T4) than in the early stage tumors (T1 and T2) (p=0.015). The frequency of LOH at the 17p13 locus in N0, N1, N2 and N3 tumors was 51 out of 96 (53%), 12 out of 18 (67%), 33 out of 51 (65%) and one out of two (50%), respectively. The frequency of LOH appeared to be slightly higher in the lymph node metastasis positive tumors but the difference was not statistically significant. The frequency of LOH at the 17p13 locus in stages I, II, III and IV cases was 12 out of 29 (41%), 22 out of 42 (52%), 17 out of 27 (63%) and 46 out of 69 (67%), respectively. The frequency of LOH was not only significantly higher in the stage IV cases than in the stage I cases (p=0.02) but was also significantly higher in the advanced stage cases (stages III and IV) than in the early stage cases (stages I and II) (p=0.022).
DISCUSSION
This is the first report to point out differences in HNSCC at different regions of origin from the point of view of the genetic aspects of the tumors.
The frequency of allelic loss at the 9p21, 3p21 and 17p13 loci was reported to be very high using multiple microsatellite markers emcompassing the loci . However, there have been few reports concerning differences in the frequencies of allelic loss in different locations of head and neck cancers. In our study, the frequencies of allelic loss in hypopharyngeal cancers were extremely high using all microsatellite markers encompassing three independent loci, i.e., 3p21, 9p21 and 17p13. Allelic loss in laryngeal cancers was also very high compared with hypopharyngeal cancers. In contrast, the frequencies of allelic loss in oral cancers were very low with all microsatellite markers used, and was approximately half that in hypopharyngeal cancers. Our Fig. 2 . Difference in the frequencies of LOH in HNSCC. DNA was extracted from cancer specimens and lymphocytes of the same patients and subjected to PCR using specific primers; D3S1067 (3p21), IFNA & D9S171 (9p21) and TP53 (17p13). The frequencies of LOH are shown in the percentage column for each site of HNSCC. Significant differences are seen in comparison between the frequencies of LOH of oral cancers and of hypopharyngeal cancers, and so on (see Table 2 and text). , 3p21; , 9p21; , 17p13; o.c., oral cavity; MP, mesopharynx; HP, hypopharynx.
results indicate that there are obvious differences in the frequencies of allelic loss between oral cancers and hypopharyngeal and laryngeal cancers. This idea of tissue specificity is supported by the fact that the frequencies of LOH at 3p21 and at 9p21 in maxillary cancers are very low and there were significant differences between the frequencies of LOH in maxillary cancers and hypopharyngeal cancers (see Tables 1 and 2) , which indicates that the mesopharynx is a boundary for genetic events in the process of carcinogenesis. Although all of these tumors were diagnosed as squamous cell carcinomas, the process of carcinogenesis may be different in tumors located in different parts of the head and neck. Hypopharyngeal and laryngeal cancers that have very frequent allelic loss should give rise to tumors as the allelic losses accumulate in order. However, oral cancers that have infrequent allelic loss should give rise to tumors in other as yet unknown ways. We hypothesize that the accumulation of several abnormalities of genes results in the formation of cancers, and that the quality and quantity of these abnormalities must influence the degree of malignancy. Although there was no significant correlation between LOH at 9p21 and localization, clinical stage, size and lymph node involvement of the tumor in our previous report (Matsuura et al. 1998) or in this study, there was a significant correlation between LOH at 3p21 and lymph node involvement. Further, there was a significant correlation between LOH at 3p21 and clinical stage of disease. In contrast, there was not only a significant correlation between LOH at 17p13 and tumor size, but, there was also a significant correlation between LOH at 17p13 and clinical stage of disease. These results suggest that the loss of function of a tumor suppressor gene(s) at the 3p21 locus empowers the tumor to metastasize to regional lymph nodes and that the loss of function of a tumor suppressor gene(s) at the 17p13 locus (e.g. p53) empowers the tumor to grow more rapidly.
